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OBJECTIVES: To investigate whether the preventive use
of cranberry capsules in long-term care facility (LTCF) res-
idents is cost-effective depending on urinary tract infection
(UTI) risk.
DESIGN: Economic evaluation with a randomized con-
trolled trial.
SETTING: Long-term care facilities.
PARTICIPANTS: LTCF residents (N = 928, 703 female,
median age 84), stratified according to UTI risk.
MEASUREMENTS: UTI incidence (clinically or strictly
defined), survival, quality of life, quality-adjusted life years
(QALYs), and costs.
RESULTS: In the weeks after a clinical UTI, participants
showed a significant but moderate deterioration in quality
of life, survival, care dependency, and costs. In high-UTI-
risk participants, cranberry costs were estimated at €439
per year (1.00 euro = 1.37 U.S. dollar), which is €3,800
per prevented clinically defined UTI (95% confidence inter-
val = €1,300–infinity). Using the strict UTI definition, the
use of cranberry increased costs without preventing UTIs.
Taking cranberry capsules had a 22% probability of being
cost-effective compared with placebo (at a willingness to
pay of €40,000 per QALY). In low-UTI-risk participants,
use of cranberry capsules was only 3% likely to be cost-
effective.
CONCLUSION: In high-UTI-risk residents, taking cran-
berry capsules may be effective in preventing UTIs but is
not likely to be cost-effective in the investigated dosage,
frequency, and setting. In low-UTI-risk LTCF residents,
taking cranberry capsules twice daily is neither effective
nor cost-effective. J Am Geriatr Soc 62:111–116, 2014.
Key words: economic evaluation; geriatrics; long-term
care facility; urinary tract infection; prevention;
cranberry
Urinary tract infection (UTI) is a common bacterialinfection in residents of long-term care facilities
(LTCFs).1–4 The effectiveness of the use of cranberry cap-
sules to prevent UTIs was assessed in a randomized con-
trolled trial.5 In residents with high UTI risk, taking
cranberry capsules twice daily reduced the incidence of
clinically defined UTI by 26%. No reduction was found
for strictly defined UTI or in residents with low UTI risk.
The current brief report investigates the effect of UTI on
health and costs and whether the preventive use of cran-
berry capsules in LTCFs is cost-effective.
METHODS
This economic evaluation was part of a double-blind ran-
domized placebo-controlled multicenter trial.5 Residents
from LTCFs (N = 928, median age 84, 703 female) were
randomized to receive cranberry or placebo capsules twice
daily for 12 months. The cranberry capsules contained
500 mg of the product with 1.8% proanthocyanidins
(9 mg). Participants were stratified according to UTI risk
(including long-term catheterization, diabetes mellitus, ≥1
UTIs in the preceding year). Main outcomes of the trial
were incidence of UTI according to a clinical definition
(following clinical practice guidelines for residents in
LTCFs) and a strict definition (with confirmation by a
positive dipslide or culture).5
Cost-Effectiveness and Cost-Utility Analysis
The economic evaluation consisted of a cost-effectiveness
analysis (CEA) from a narrow perspective and a cost-
utility analysis (CUA) from a lifelong societal perspective
for high- and for low-UTI-risk participants.
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The CEA from a narrow perspective was based
directly on the trial data during follow-up, to prevent
modeling assumptions. Effectiveness was measured accord-
ing to the number of clinically defined and strictly defined
UTIs (first and recurrent). Costs included only cranberry
use.
The CUA was performed from a lifelong societal
perspective. Costs, survival and quality-adjusted life years
(QALYs) were estimated using a non-Markovian state-
transition model, with parameters estimated from the
trial data. In this model, the cranberry and placebo
groups differed in their clinically defined UTI infection
rate but not in the consequences per UTI. Thus, it was
implicitly assumed that prevented UTIs are comparable
with nonprevented UTIs and that cranberry use has no
relevant effects other than cranberry costs and UTI
prevention. These modeling assumptions were made
beforehand because it was clear that the study would
have insufficient power for a direct randomized economic
comparison.
In the CUA model (Figure 1), participant time was cate-
gorized into five model states: during the initial 2 months
and before the first UTI, after the initial 2 months and
before the first UTI, during the first month after the first
UTI, after the first month after the first UTI, and death.
UTI Infection Rate and Mortality
Three separate annual UTI infection rates were estimated
in a combined Poisson regression analysis. Infection rates
in the cranberry and placebo groups were different after
the first 2 months and before the first UTI (State 2). No
effect of cranberry use was seen in the initial 2 months
(State 1) or after the first UTI (States 3 and 4). Occurrence
of a first UTI was associated with greater mortality during
the subsequent month (State 3) and after the subsequent
month (State 4). Annual mortality was estimated in a
combined Poisson regression analysis.
Utilities
Utilities represent the valuation of the quality of life of the
participants on a scale anchored at 1 (perfect health) and
0 (as bad as being dead). Utility was measured using the
EQ-5D classification system, which is a brief questionnaire
with five domains (mobility, self-care, usual activities, pain
and discomfort, and anxiety and depression), each with
three levels (no, some, or extreme problems).6 Utility val-
ues were assigned to the EQ-5D using the Dutch tariff.7
Valuations were also obtained using a visual analog scale
(VAS) ranging from 100 (perfect health) to 0 (worst imag-
inable health), which was transformed to a utility scale
using a power transformation.8 EQ-5D and VAS measure-
ments were obtained from the participants (11%) or from
well-informed nurses or caregivers (89%).
Utility before and after the first UTI (parameters U0
and U2) was estimated from EQ-5D and VAS measure-
ments obtained at baseline and after 6 and 12 months
(correcting for time). In addition, UTIs were assumed to
have a short-term effect on utility for 2 weeks. Additional
EQ-5D and VAS measurements were obtained in 123 par-
ticipants with a clinically defined UTI (from 17 different
LTCFs) every 3 days over 3 weeks after the UTI to esti-
mate this effect. The utility decrement during the UTI was
estimated as the difference between the average over the
first 2 weeks and the average over the third week
(parameter DU, attributed to State 3 with parameter
U1 = U2DU 9 14/30).
Costs
The economic model included two types of costs. The first
was the costs of cranberry use (parameter c1). These costs
were estimated at €439 annually (€0.62 per intake) based
on one capsule twice a day, a market price of €44 for 180
capsules, on average 45 seconds of nursing time per
capsule (estimated using time registrations), nursing time
valued at €30 per hour,9 and 97% adherence (1.00 euro =
1.37 U.S. dollar).
The second type of costs were the costs associated
with each UTI (parameter c2, Table 1), including costs of
UTI diagnostics and antibiotic treatment, additional care
by the elderly-care physician, additional nursing care, and
hospitalizations. Costs of UTI diagnostics and antibiotic
treatment per UTI were calculated from actual costs in
patient records for each UTI (n = 548). Additional care by
the elderly-care physician was estimated at on average €25
per UTI (10–30 minutes of time, valued at €111 per
hour9,10). Additional nursing costs during the 2 weeks
after a UTI were estimated in proportion to the Care
Dependency Scale,11 which measures 15 items of basic
care needs, each rated on a 5-point scale (1 = completely
dependent; 5 = completely independent). Hospitalizations
costs were recorded for six UTIs (1% of n = 548), all in
high-UTI-risk participants. Costs per hospitalization ran-
ged from €3,000 (for 6 days of normal hospital care) to
€15,000 (for 7 days of normal care and 5 days of intensive
care).9
Figure 1. The state-transition model used in the economic evaluation. UTI = Urinary Tract Infection.
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Costs were presented in euros, at 2013 prices (updated
if necessary using the general Dutch consumer price
index).12 Included costs were all medical costs, which for
this trial population coincided with the societal
perspective.
Lifelong Outcomes
The model shown in Figure 1 and Table 1 was used to
extrapolate the trial period to lifelong outcomes. Life
expectancy was calculated as the expected total time
spent in States 1 to 4. QALYs were calculated by weigh-
ing the time in each state with the appropriate utility
value, discounted at d = 4%.13 Using this approach, the
following formula for the difference in discounted QALYs
between the cranberry and the placebo groups was
derived:
DQALY ¼ðk0  k1Þ ðl0 þ dÞðk0 þ l0 þ dÞðk1 þ l0 þ dÞ
















where T denotes the initial 2 months and S denotes the
1 month after the first UTI. A similar formula was derived
for the discounted costs. The models for the cranberry and
placebo groups differ only in their value for the infection
rate (k1 and k0, respectively) and in their value for the
annual cranberry costs (c1 and 0, respectively).
Statistical Analysis
Uncertainty due to sampling error for the estimated life-
long outcomes was assessed using bootstrap analysis
(using B = 10,000 bootstrap samples). For each boot-
strap sample, all model parameters (Table 1) were
re-estimated, and the lifelong formulae were used to esti-
mate outcome. The 95% confidence intervals (CIs) for
the parameters and outcomes were assessed from the 2.5
and 97.5 percentiles among the bootstrap samples.10 Sta-
tistical analyses for the economic evaluation were per-
formed in R version 2.13.0 (Vienna, Austria).
Depending on the willingness to pay (WTP) for
obtained effectiveness, cranberry use is estimated to be
cost-effective if it has a better net benefit (NB = WTP
9 effectivenesscosts) than placebo. Cost-effectiveness
acceptability curves were used to plot the probability that
cranberry use is more cost-effective than placebo as a func-
tion of WTP (estimated as the percentage of bootstrap
samples in which cranberry use had a better estimated
NB). Confidence intervals for the cost-effectiveness ratio
were calculated as WTP values for which the difference in
net benefit was not significantly different.14 The base-case
CUA compared total societal costs with QALYs calculated
from the Dutch tariff for the EQ-5D at a WTP of €40,000
per QALY.
RESULTS
Effect of UTIs on Mortality, Utility, and Costs
Quality of life was significantly but moderately worse dur-
ing a UTI; comparing the first 2 weeks after a UTI with
the third week, averages were 0.341 versus 0.379 for the
Table 1. Parameters for the Health–Economic Model,






UTI infection ratesb in low-UTI-risk participants
Rate before the first UTI,
during the first 2 months (k0)
0.32 (0.23–0.40)
Hazard ratio before first UTI,
after first 2 months (k1/k0)
a,c
1.41 (0.77–1.86)




UTI infection ratesb in high-UTI-risk participants
Rate before the first UTI,
during the first 2 months (k0)
0.81 (0.68–0.94)
Hazard ratio before first UTI,
after first 2 months (k1/k0)
a,c
0.75 (0.52–0.94)





Rate before the first UTI (l0) 0.33 (0.29–0.38)
Hazard ratio during the




Hazard ratio after the first
month after first UTI (l2/l0)
c
1.32 (0.87–1.67)
Utilitiesd based on EQ-5D






first 2 weeks after
first UTI (DU)c
0.04 (0.01–0.07)
Utilitiesd based on visual analog scale





first 2 weeks after
first UTI (DU)
0.03 (0.00–0.05)




Cost per UTI, €










Cost of hospitalizations 40 (8–74)
Total cost per (prevented
or nonprevented) UTI (c2)
196 (111–278)
a Only in the cranberry group.
b Annual event rate.
c Relative or absolute change during the specified period, compared with
the base value.
d Valuation of quality of life of the participants on a scale anchored at 1
(perfect health) and 0 (as bad as being dead).
UTI = urinary tract infection.
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EQ-5D (difference 0.038, P = .02) and 0.727 versus 0.753
for the VAS (difference 0.026, P = .03).
Mortality in the month after a first UTI was 3.6 times
as great as in residents without a UTI (Table 1). After
more than a month, the difference was not statistically
significant.
The Care Dependency Scale was also significantly but
moderately worse during a UTI (40.7 vs 42.0; difference
1.2; P = .01), with an estimated 4% increase in nursing
costs in the 2 weeks after a UTI. Total healthcare costs
associated with (prevented) UTIs were estimated at €196,
primarily consisting of the additional nursing care (61%),
followed by hospitalization costs (20%), care by the
elderly-care physician (13%), diagnostics (4%). and antibi-
otic treatment (2%).
High-UTI-Risk Participants
Cranberry use on average prevented 0.09 clinically defined
UTIs (0.69 vs 0.78, P = .32) during the trial follow-up (of
289 vs 289 days, P = .99). The associated costs were esti-
mated at €3,800 per prevented UTI (95% CI = €1,300–
infinity). Cranberry use did not prevent strictly defined
UTIs during follow-up (0.28 vs 0.22, P = .30).
From a lifetime societal perspective, the reduced clini-
cal UTI infection rate resulted in improvements in other
health outcomes and costs, although not significantly
(Table 2). Life expectancy was estimated to be approxi-
mately 2 weeks longer (0.044 years, 95% CI = 0.023–
0.091). The savings on costs associated with UTIs were
much smaller than the cranberry costs, use of cranberry
capsules increased lifelong total costs by €941 (95%
CI = €779–1,055). Whether this cost difference is econom-
ically acceptable depends on how much one is willing to
pay for the health improvement in terms of QALYs
(Figure 2). For relatively low willingness to pay up to
€20,000 per QALY, the probability that cranberry use is
more cost-effective than placebo was estimated at less than
1% (in the base-case analysis using the EQ-5D). At
€40,000 per QALY, the probability that cranberry use is
cost-effective was estimated at 22%. When the VAS was
used instead of the EQ-5D, more value was assigned to
quality of life during the added life expectancy. As a
result, the estimated probability that cranberry use is more
cost-effective than placebo at a willingness to pay of
€20,000 and €40,000 per QALY was 16% and 53%,
respectively (Figure 2).
The economic assessment would be more favorable to
cranberry use if the costs of cranberry use were lower or
the savings per prevented UTI were higher. The costs of
cranberry use would need to decrease from €439 to €300
to make cranberry and placebo equally cost-effective. Simi-
larly, the savings per prevented clinical UTI would need to
increase from €196 to €1,704 to make cranberry and
placebo equally cost-effective.
Low-UTI-Risk Participants
In the low-UTI-risk participants, because no effect of cran-
berry use on UTI infection rate was found, there was also
Table 2. Mean Lifelong Health-Economic Outcomes of Treatment with or without Cranberry, Estimated from the
Health-Economic Model
Outcome Cranberry Placebo Difference (95% Confidence Interval)
Low UTI risk
Number of UTIsa,b 2.13 1.84 0.29 (0.06–0.60)
Life expectancy, yearsa 2.53 2.59 0.06 (0.14–0.05)
QALYs based on EQ-5Dc 0.83 0.85 0.02 (0.05–0.01)
QALYs based on VASc 1.69 1.73 0.04 (0.09–0.03)
Cost of cranberry use, € 1,012 0 1,012 (863–1,120)
Cost of diagnostics, € 15 13 2 (1–5)
Cost of antibiotic treatment, € 5 4 1 (1–2)
Cost of elderly-care physician, € 47 40 7 (2–15)
Cost of additional nursing care, € 228 196 32 (22–68)
Cost of hospitalizations, € 76 65 11 (13–23)
Total UTI cost, € 1,383 318 1,065 (889–1,183)
High UTI risk
Number of UTIa,b 2.75 2.96 0.21 (0.42–0.04)
Life expectancy, yearsa 2.45 2.40 0.05 (0.02–0.09)
QALYs based on EQ-5Dc 0.81 0.79 0.02 (0.01–0.03)
QALYs based on VASc 1.64 1.61 0.03 (0.01–0.06)
Cost of cranberry use, € 982 0 982 (814–1,099)
Cost of diagnostics, € 20 22 2 (4–1)
Cost of antibiotic treatment, € 7 8 1 (2–1)
Cost of elderly-care physician, € 61 66 5 (10–1)
Cost of additional nursing care, € 298 323 25 (49–13)
Cost of hospitalizations, € 99 107 8 (17–9)
Total UTI cost, € 1,467 526 941 (779–1,055)
a Undiscounted.
b Lifelong, both first and other urinary tract infections (UTIs), using the clinical definition.
c Quality-adjusted life years (QALYs; life expectancy weighed by utility for quality of life).
VAS = Visual Analog Scale.
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no difference in the other health outcomes. The only dif-
ference was the estimated lifelong costs of €1,012 for cran-
berry use. As a result, it is highly unlikely that use of
cranberry capsules is cost-effective in low-UTI-risk resi-
dents (probability <3%, regardless of willingness to pay
per QALY).
DISCUSSION
This study investigated whether the use of cranberry cap-
sules is more cost-effective than placebo based on data
from a randomized controlled trial.5 In participants with
low UTI risk, the use of cranberry capsules did not prevent
UTIs, and consequently, their use is not cost-effective. In
high-UTI-risk participants, there were fewer clinically
defined UTIs. Moreover, there was a significant, but mod-
erate, short-term effect of those UTIs on quality of life and
care dependency. Most of the QALY gain was due to the
prevented UTI mortality, resulting in a gain in life expec-
tancy of approximately 2 weeks. This relative 1.5%
improvement in life expectancy is consistent with the esti-
mated mortality attributable to UTI (7.7%) combined with
the 26% treatment effect.5
Savings on prevented UTIs partly compensate for the
costs of the cranberry capsules, but using a lifelong perspec-
tive, those savings added up to approximately €50. As a
result, the overall cost difference is about equal to the costs
of the cranberry capsules, estimated at €439 per year or at
€3,800 per prevented clinically defined UTI. The health gain
in terms of QALYs was small in comparison with the costs,
so use of cranberry capsules was not likely to be cost-
effective (22% for a WTP threshold of €40,000 per QALY).
Options to Improve Cost-Effectiveness
Cranberry use does not constitute a low-cost strategy to
prevent UTIs.15 The estimated price for the capsules was
lower than the price estimated previously (€0.24 vs CAN
$0.73  €0.61),16 but the overall costs per capsule were
somewhat similar because of the added nursing time in the
current study. The previous study estimated the costs per
prevented UTI at CAN$1,890, which was acknowledged
as quite high.16 That study suggested that cranberry use
could be cost-effective if the strength or size of the cran-
berry product could be reduced without reducing effective-
ness. In the current study, a preventive effect was seen
with the cranberry capsules after 2 months. It is unknown
whether lowering the frequency after those 2 months
would change not only the costs, but also the effect.
Second, the cost-effectiveness of cranberry use would
also be more favorable in settings in which the savings per
prevented UTI were higher. In the current study, these
savings would need to be eight times as high to make cran-
berry and placebo equally cost-effective. This seems unre-
alistic for the Dutch LTCF setting, although in other
healthcare systems, residents with UTIs may more
frequently be referred to a hospital than the 1% in the cur-
rent study population. Similarly, in noninstitutionalized
vulnerable older persons, the savings associated with pre-
vented UTIs may be higher because of the need for addi-
tional formal and informal care during and after a UTI.
Third, the high-UTI-risk criteria included diabetes
mellitus, long-term catheterization, and UTI in the preced-
ing year. Better identification of older persons at high UTI
risk may also improve cost-effectiveness.
Limitations
There are several complicating factors in analyzing cost-
effectiveness in vulnerable older persons in LTCFs. The
first is how to value the residents’ health. According to the
EQ-5D, health during the 2-week life expectancy gain was
valued at approximately 40%, whereas according to the
VAS, this gain would be valued at approximately 70%. In
accordance with the study protocol, the EQ-5D was con-
sidered to be more appropriate than the VAS because the
EQ-5D provides a societal valuation and because the
descriptions it requires are less subjective than the valua-
tions that the VAS requires.17 Consistent with the high
percentage of participants with dementia (76%) and the
high percentage of participants for whom family provided
informed consent (84%),5 nurses mostly provided the util-
ity measures (89%), and little is known about the validity
of proxy VAS valuations in a LTCF context. Considering
the often poor health of LTCF residents, the VAS valua-
tions appear high.
Another factor is the high costs of standard LTCF
care, amounting to approximately €80,000 annually in the
Figure 2. Cost-effectiveness acceptability curves, for high-uri-
nary tract infection (UTI)-risk participants (the probability
that cranberry use is more cost-effective than placebo,
depending on how much one is willing to pay for a quality-
adjusted life year (QALY), based on utility measured using
the EQ-5D or the visual analog scale (VAS)).
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Netherlands.9,18 Including these high costs in the analysis
would make any life-prolonging treatment too expensive,
even if the treatment itself was cost free. In the analysis,
the 2-week life expectancy gain would add approximately
€1,500 to the costs associated with cranberry use, confirm-
ing the conclusion that use of cranberry capsules is not
likely to be cost-effective. Dutch guidelines for economic
evaluations in health care recommend including costs asso-
ciated with additional life time only if they are related to
the primary intervention, which was not the case in the
current analysis.
Third, it was decided beforehand that the economic
state/transition model would be based on the clinical defi-
nition, because it was expected that it would be more pre-
dictive of outcome. Had the strict UTI definition been used
for the model, the estimated effectiveness and cost-
effectiveness would have been less favorable to the use of
cranberry capsules, confirming the conclusion that use of
cranberry capsules is not likely to be cost-effective.
Finally, this study was performed in Dutch LTCFs,
where elderly-care physicians provide medical care.19–21
The results are not automatically generalizable to vulnera-
ble older persons living at home. In LTCFs, medication pre-
scription and distribution are well organized. Because the
study capsules were added to the existing drug-dispensing
system, participants rarely missed taking a capsule,
reflected in a high adherence rate. For other settings, not
only differences in vulnerability and infection rates are
expected, but also in adherence. Moreover, at home, cran-
berry capsules can be taken without the help of nurses,
which would halve the costs of cranberry use.
CONCLUSIONS
In high-UTI-risk residents, taking cranberry capsules may
be effective in preventing UTIs but is not likely to be cost-
effective in the investigated dosage, frequency, and setting.
In low-UTI-risk LTCF residents, taking cranberry capsules
twice daily is neither effective nor cost-effective.
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